myelogenous leukemia (CML) are being recommended and include dasatinib and nilotinib. Chronic myelogenous leukemia (CML) is a myeloproliferative disorder affecting the hematopoietic stem cell compartment. It can occur in all age groups but is predominantly a disease of adults, accounting for 20% of adult leukemias. Drugs that are highly effective in treating most cases of chronic myeloid leukemia (CML) first became available in There's no accurate information yet on how long patients treated with these drugs may live. All that's known is that most patients who have been treated with these drugs, starting in (or even before), are still alive.
Chronic myelogenous leukemia can also be called chronic myeloid leukemia and chronic granulocytic leukemia. It typically affects older adults and rarely occurs in children, though it can occur at any age. Advances in treatment have contributed to a greatly improved prognosis for people with chronic myelogenous leukemia. CML is a fairly slow growing leukemia, but it can change into a fast-growing acute leukemia that's hard to treat. CML occurs mostly in adults, but very rarely it occurs in children, too. In general, their treatment is the same as for adults.
(Redirected from Adult Chronic Leukemia) Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. Chronic myeloid leukemia (also called CML or chronic myelogenous leukemia) is a chronic (long-term, slowly developing) form of leukemia. Leukemia is a type of cancer of cells in the blood and bone .
The phase of chronic myelogenous leukemia refers to the aggressiveness of the disease. Your doctor determines the phase by measuring the proportion of diseased cells to healthy cells in your blood or bone marrow. A higher proportion of diseased cells means chronic myelogenous leukemia . Most cases of CML occur in adults. From to , approximately 2 percent of all cases of CML occurred in children, adolescents and young adults less than age The treatment of children with CML is not standardized.